

## SmartCella publishes its 2025 Annual Report

Following yesterday's invitation to the Annual General Meeting, SmartCella Holding AB ("SmartCella") today publishes its 2025 Annual Report. The English version is an extended, unaudited translation of the official 2025 Annual Report in Swedish. Both reports are available on [SmartCella's website](#).

2025 was a year of both strategic and operational progress for SmartCella. Significant highlights included continued expansion of the Extroducer® partnership pipeline, the first patient dosed using the Extroducer® technology in a Phase IIb study with XyloCor Therapeutics, and preparations for SmartCella's clinical trial for pancreatic cancer. SmartCella also strengthened the organization through senior leadership appointments and the establishment of a Scientific Advisory Board.

In the 2025 Annual Report, Chairperson Christian Kinch and CEO Niklas Prager comment on SmartCella's performance and on the potential ahead following the decision to sharpen the focus on targeted drug delivery:

"In 2025, the Extroducer® pipeline continued to strengthen. A significant highlight was when XyloCor Therapeutics dosed the first patient using the Extroducer® platform in their Phase IIb trial, which was a major validation of our platform. In response to a shifting biopharma landscape, we made the decisive move to sharpen our focus on targeted drug delivery and streamline our business model, reducing our cost base and moving closer to cash flow breakeven. We enter 2026 with a clear path forward: a leaner, faster, and more focused organization dedicated to solving the last mile of targeted drug delivery."

The SmartCella Annual 2025 report is published in Swedish, with a translation into English. In the event of any discrepancies between the language versions, the Swedish version shall prevail.

### Contact

Nina Nornholm, Head of Communication & Investor Relations +46 708 550 356

### About SmartCella

SmartCella is a global drug delivery company pioneering innovative delivery solutions for targeted therapies. The main technology, the Extroducer®, is a modality-agnostic endovascular delivery device designed for localized delivery to hard-to-reach organs, tumors, and tissues. The Extroducer® is FDA 510(k)-cleared for use in peripheral (including abdominal) tissues to inject diagnostic and therapeutic solutions into the perivascular space. It is currently in clinical investigation for additional indications. SmartCella commercializes the Extroducer® through non-exclusive licensing agreements with global biotech and pharma companies, enabling broad application across all development phases. The company also offers a proprietary stem cell platform for the delivery of mRNA therapeutics, featuring a proof-of-concept program focused on Osteoarthritis.

Founded in 2014, SmartCella is built on world-class research from Sweden's Karolinska Institutet.

Read more [www.smartcella.com](http://www.smartcella.com) and follow SmartCella on [LinkedIn](#)